{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:37:44Z","timestamp":1785411464904,"version":"3.56.0"},"posted":{"date-parts":[[2026,7,9]]},"group-title":"Cancer Biology","reference-count":91,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["R37CA279341"],"award-info":[{"award-number":["R37CA279341"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["Robert Citrone, George Walker, & Mark Weinberger \u2013 PCF VAlor Young Investigator Award"],"award-info":[{"award-number":["Robert Citrone, George Walker, & Mark Weinberger \u2013 PCF VAlor Young Investigator Award"]}],"id":[{"id":"https:\/\/ror.org\/01npwtv09","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Metastatic prostate cancer (PCa) continues to be a major cause of death in males, despite advances in treatment. Most treatment focuses on targeting the Androgen Receptor (AR), the main oncogene responsible for driving most prostate tumors. Despite these therapies targeting AR, the majority of patients still succumb to AR-driven disease. Therefore, there is a critical need for understanding how AR functions to promote prostate cancer growth and identify alternative therapeutic targets in AR-driven PCa. One avenue garnering attention is targeting epigenetic regulators that promote AR-activity; however, the importance of epitranscriptomic regulators, like those that modify mRNAs, is not well understood. Here, we identify a new role for the key catalytic subunit of the RNA N6-methyladenosine (m\n                  <jats:sup>6<\/jats:sup>\n                  A) transferase complex, METTL3, as an AR-coregulator. METTL3 is overexpressed in prostate tumors compared to normal tissue, and METTL3 protein is elevated in AR-expressing cell lines. Depletion of METTL3 significantly reduces proliferation of cancer cells and has no effect on the growth of non-transformed prostate epithelial cells, despite decreasing global m\n                  <jats:sup>6<\/jats:sup>\n                  A levels on mRNA. The catalytic activity of METTL3 is dispensable for the growth of both non-transformed and PCa cell lines, as pharmacologic inhibition of METTL3 does not inhibit proliferation, despite the reduction of global m\n                  <jats:sup>6<\/jats:sup>\n                  A on mRNA. Overexpression of both wild-type and catalytically inactive METTL3 mutants enhances cell viability and rescues cells in which METTL3 is knocked down. Finally, we report on direct interaction between AR and METTL3, their co-localization on chromatin, and reduced AR-cistromic occupancy within cells with METTL3 knockdown. Together, these findings identify a non-enzymatic role for METTL3 in supporting AR-driven transcriptional programs and PCa proliferation.\n                <\/jats:p>","DOI":"10.64898\/2026.07.08.737095","type":"posted-content","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:55:17Z","timestamp":1783605317000},"source":"Crossref","is-referenced-by-count":0,"title":["A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes prostate cancer proliferation"],"prefix":"10.64898","author":[{"given":"Raymond J.","family":"Kostlan","sequence":"first","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7954-4059","authenticated-orcid":false,"given":"John T.","family":"Phoenix","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audris","family":"Budreika","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carli D.","family":"Deegan","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina G.","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise T.","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpinder S.","family":"Bawa","sequence":"additional","affiliation":[{"name":"Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Dureja","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzna","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govinda R.","family":"Hancock","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen S.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Urology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Solanki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Vander Griend","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean W.","family":"Fanning","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-2657","authenticated-orcid":false,"given":"Steven","family":"Kregel","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Loyola University Chicago, Maywood, IL, USA"},{"name":"Department of Urology, Loyola University Chicago, Maywood, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026071304000824000_2026.07.08.737095v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228"},{"key":"2026071304000824000_2026.07.08.737095v1.2","unstructured":"Institute, N.C. (2025)."},{"key":"2026071304000824000_2026.07.08.737095v1.3","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1941.01210140043004"},{"key":"2026071304000824000_2026.07.08.737095v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.04.038"},{"key":"2026071304000824000_2026.07.08.737095v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01244-6"},{"key":"2026071304000824000_2026.07.08.737095v1.6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8456"},{"key":"2026071304000824000_2026.07.08.737095v1.7","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","year":"2015","journal-title":"Translational Andrology and Urology"},{"key":"2026071304000824000_2026.07.08.737095v1.8","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060936"},{"key":"2026071304000824000_2026.07.08.737095v1.9","doi-asserted-by":"crossref","first-page":"116338","DOI":"10.1016\/j.biopha.2024.116338","article-title":"Androgen receptor cofactors: a potential role in understanding prostate cancer","volume":"173","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2026071304000824000_2026.07.08.737095v1.10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.300194"},{"key":"2026071304000824000_2026.07.08.737095v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp220"},{"key":"2026071304000824000_2026.07.08.737095v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03148-4"},{"key":"2026071304000824000_2026.07.08.737095v1.13","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41588-025-02336-6","article-title":"Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer","volume":"57","year":"2025","journal-title":"Nat Genet"},{"key":"2026071304000824000_2026.07.08.737095v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature13229"},{"key":"2026071304000824000_2026.07.08.737095v1.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3776"},{"key":"2026071304000824000_2026.07.08.737095v1.16","doi-asserted-by":"crossref","unstructured":"Const\u00e2ncio, V. , Lobo, J. , Sequeira, J. , Henrique, R. and Jer\u00f3nimo, C . (2025) Prostate cancer epigenetics\u2014from pathophysiology to clinical application. Nature Reviews Urology.","DOI":"10.1038\/s41585-024-00991-8"},{"key":"2026071304000824000_2026.07.08.737095v1.17","doi-asserted-by":"publisher","DOI":"10.1261\/rna.041178.113"},{"key":"2026071304000824000_2026.07.08.737095v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature12730"},{"key":"2026071304000824000_2026.07.08.737095v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.014"},{"key":"2026071304000824000_2026.07.08.737095v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3453"},{"key":"2026071304000824000_2026.07.08.737095v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.05.003"},{"key":"2026071304000824000_2026.07.08.737095v1.22","doi-asserted-by":"publisher","DOI":"10.1101\/gad.269415.115"},{"key":"2026071304000824000_2026.07.08.737095v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2015.08.021"},{"key":"2026071304000824000_2026.07.08.737095v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.01.016"},{"key":"2026071304000824000_2026.07.08.737095v1.25","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1432"},{"key":"2026071304000824000_2026.07.08.737095v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2014.3"},{"key":"2026071304000824000_2026.07.08.737095v1.27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/biom12081042","article-title":"Multifaceted Roles of the N6-Methyladenosine RNA Methyltransferase METTL3 in Cancer and Immune Microenvironment","volume":"12","year":"2022","journal-title":"Biomolecules"},{"key":"2026071304000824000_2026.07.08.737095v1.28","first-page":"621","article-title":"The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells","volume":"52","year":"2018","journal-title":"Int J Oncol"},{"key":"2026071304000824000_2026.07.08.737095v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.11.018"},{"key":"2026071304000824000_2026.07.08.737095v1.30","doi-asserted-by":"crossref","unstructured":"Chen, M. , Wei, L. , Law, C.T. , Tsang, F.H. , Shen, J. , Cheng, C.L. , Tsang, L.H. , Ho, D.W. , Chiu, D.K. , Lee, J.M. et al. (2017) RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2. Hepatology.","DOI":"10.1002\/hep.29683"},{"key":"2026071304000824000_2026.07.08.737095v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.03.021"},{"key":"2026071304000824000_2026.07.08.737095v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/nature24678"},{"key":"2026071304000824000_2026.07.08.737095v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4416"},{"key":"2026071304000824000_2026.07.08.737095v1.34","doi-asserted-by":"publisher","DOI":"10.7150\/jca.42338"},{"key":"2026071304000824000_2026.07.08.737095v1.35","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S226796"},{"key":"2026071304000824000_2026.07.08.737095v1.36","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01735-3"},{"key":"2026071304000824000_2026.07.08.737095v1.37","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0014"},{"key":"2026071304000824000_2026.07.08.737095v1.38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-020-01293-4","article-title":"Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine","volume":"19","year":"2020","journal-title":"Mol Cancer"},{"key":"2026071304000824000_2026.07.08.737095v1.39","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1002\/ctm2.426","article-title":"m(6) A modification of lncRNA PCAT6 promotes bone metastasis in prostate cancer through IGF2BP2-mediated IGF1R mRNA stabilization","volume":"11","year":"2021","journal-title":"Clin Transl Med"},{"key":"2026071304000824000_2026.07.08.737095v1.40","first-page":"3565","article-title":"m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1","volume":"24","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026071304000824000_2026.07.08.737095v1.41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-020-01267-6","article-title":"YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer","volume":"19","year":"2020","journal-title":"Mol Cancer"},{"key":"2026071304000824000_2026.07.08.737095v1.42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/nar\/gkab1247","article-title":"Regulation of AR mRNA translation in response to acute AR pathway inhibition","volume":"50","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026071304000824000_2026.07.08.737095v1.43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12935-022-02452-x","article-title":"Dynamic regulation and functions of mRNA m6A modification","volume":"22","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2026071304000824000_2026.07.08.737095v1.44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3630"},{"key":"2026071304000824000_2026.07.08.737095v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.284"},{"key":"2026071304000824000_2026.07.08.737095v1.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"2026071304000824000_2026.07.08.737095v1.47","doi-asserted-by":"crossref","unstructured":"Efstathiou, E. , Titus, M. , Wen, S. , Hoang, A. , Karlou, M. , Ashe, R. , Tu, S.M. , Aparicio, A. , Troncoso, P. , Mohler, J. et al. (2014) Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. European urology.","DOI":"10.1016\/j.eururo.2014.05.005"},{"key":"2026071304000824000_2026.07.08.737095v1.48","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000141580.30910.57"},{"key":"2026071304000824000_2026.07.08.737095v1.49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0226"},{"key":"2026071304000824000_2026.07.08.737095v1.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0142"},{"key":"2026071304000824000_2026.07.08.737095v1.51","doi-asserted-by":"crossref","unstructured":"Esteva-Socias, M. and Aguilo, F . (2024) METTL3 as a master regulator of translation in cancer: mechanisms and implications. NAR Cancer, 6.","DOI":"10.1093\/narcan\/zcae009"},{"key":"2026071304000824000_2026.07.08.737095v1.52","first-page":"1663","article-title":"Expression patterns and a prognostic model of m(6)A-associated regulators in prostate adenocarcinoma","volume":"14","year":"2020","journal-title":"Biomark Med"},{"key":"2026071304000824000_2026.07.08.737095v1.53","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/and.14422","article-title":"METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner","volume":"54","year":"2022","journal-title":"Andrologia"},{"key":"2026071304000824000_2026.07.08.737095v1.54","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2217\/fon-2020-0330","article-title":"The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer","volume":"16","year":"2020","journal-title":"Future Oncol"},{"key":"2026071304000824000_2026.07.08.737095v1.55","doi-asserted-by":"crossref","first-page":"602485","DOI":"10.3389\/fgene.2020.602485","article-title":"The Identification of Critical m(6)A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma","volume":"11","year":"2020","journal-title":"Front Genet"},{"key":"2026071304000824000_2026.07.08.737095v1.56","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.7150\/jca.55140","article-title":"Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer","volume":"12","year":"2021","journal-title":"J Cancer"},{"key":"2026071304000824000_2026.07.08.737095v1.57","doi-asserted-by":"crossref","first-page":"119180","DOI":"10.1016\/j.lfs.2021.119180","article-title":"The FTO m(6)A demethylase inhibits the invasion and migration of prostate cancer cells by regulating total m(6)A levels","volume":"271","year":"2021","journal-title":"Life Sci"},{"key":"2026071304000824000_2026.07.08.737095v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00656-3"},{"key":"2026071304000824000_2026.07.08.737095v1.59","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41419-023-06287-w","article-title":"METTL3 promotes colorectal cancer progression through activating JAK1\/STAT3 signaling pathway","volume":"14","year":"2023","journal-title":"Cell Death & Disease"},{"key":"2026071304000824000_2026.07.08.737095v1.60","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-022-00968-y"},{"key":"2026071304000824000_2026.07.08.737095v1.61","doi-asserted-by":"crossref","first-page":"1096071","DOI":"10.3389\/fgene.2022.1096071","article-title":"Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer","volume":"13","year":"2023","journal-title":"Frontiers in genetics"},{"key":"2026071304000824000_2026.07.08.737095v1.62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cjp2.319","article-title":"Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression","volume":"9","year":"2023","journal-title":"J Pathol Clin Res"},{"key":"2026071304000824000_2026.07.08.737095v1.63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1228"},{"key":"2026071304000824000_2026.07.08.737095v1.64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053701"},{"key":"2026071304000824000_2026.07.08.737095v1.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.003"},{"key":"2026071304000824000_2026.07.08.737095v1.66","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/cancers17020306","article-title":"The homeobox transcription factor NKX3. 1 displays an oncogenic role in castration-resistant prostate cancer cells","volume":"17","year":"2025","journal-title":"Cancers"},{"key":"2026071304000824000_2026.07.08.737095v1.67","doi-asserted-by":"crossref","unstructured":"Budreika, A. , Phoenix, J.T. , Kostlan, R.J. , Deegan, C.D. , Ferrari, M.G. , Young, K.S. , Fanning, S.W. and Kregel, S . (2025) The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells. Cancers (Basel ), 17.","DOI":"10.3390\/cancers17020306"},{"key":"2026071304000824000_2026.07.08.737095v1.68","first-page":"3997","article-title":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM","volume":"1303","year":"2013","journal-title":"arXiv preprint arXiv"},{"key":"2026071304000824000_2026.07.08.737095v1.69","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137"},{"key":"2026071304000824000_2026.07.08.737095v1.70","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr539"},{"key":"2026071304000824000_2026.07.08.737095v1.71","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq033"},{"key":"2026071304000824000_2026.07.08.737095v1.72","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv416"},{"key":"2026071304000824000_2026.07.08.737095v1.73","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz332"},{"key":"2026071304000824000_2026.07.08.737095v1.74","doi-asserted-by":"crossref","unstructured":"Aleksander, S.A. , Balhoff, J.P. , Carbon, S. , Cherry, J.M. , Ebert, D. , Feuermann, M. , Gaudet, P. , Harris, N.L. , Hill, D.P. and Kalita, P . (2025) The Gene Ontology knowledgebase in 2026. Nucleic Acids Research, 54, gkaf1292.","DOI":"10.1093\/nar\/gkag678"},{"key":"2026071304000824000_2026.07.08.737095v1.75","doi-asserted-by":"publisher","DOI":"10.1038\/75556"},{"key":"2026071304000824000_2026.07.08.737095v1.76","doi-asserted-by":"crossref","unstructured":"Phoenix, J.T. , Budreika, A. , Schmeck, D.A. , Kostlan, R.J. , Ferrari, M.G. , Young, K.S. , Rogers, C.S. , Deegan, C.D. , Bienko, M.W. , Bergom, H.E. et al. (2025) SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer. bioRxiv.","DOI":"10.1101\/2025.07.18.664790"},{"key":"2026071304000824000_2026.07.08.737095v1.77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03536-w"},{"key":"2026071304000824000_2026.07.08.737095v1.78","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00041.2017"},{"key":"2026071304000824000_2026.07.08.737095v1.79","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2767-9764.CRC-22-0362","article-title":"Regulation of Prostate Androgens by Megalin and 25-hydroxyvitamin D Status: Mechanism for High Prostate Androgens in African American Men","volume":"3","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026071304000824000_2026.07.08.737095v1.80","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.05958-11"},{"key":"2026071304000824000_2026.07.08.737095v1.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.05.041"},{"key":"2026071304000824000_2026.07.08.737095v1.82","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa178"},{"key":"2026071304000824000_2026.07.08.737095v1.83","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.380865"},{"key":"2026071304000824000_2026.07.08.737095v1.84","doi-asserted-by":"crossref","first-page":"1272932","DOI":"10.3389\/fendo.2023.1272932","article-title":"Editorial: Hormone resistance in cancer","volume":"14","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026071304000824000_2026.07.08.737095v1.85","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12957-025-03939-3","article-title":"ALOXE3 expression predicts poor prognosis and modulates immune infiltration in colon adenocarcinoma","volume":"23","year":"2025","journal-title":"World J Surg Oncol"},{"key":"2026071304000824000_2026.07.08.737095v1.86","doi-asserted-by":"crossref","first-page":"115411","DOI":"10.1016\/j.intimp.2025.115411","article-title":"ALOXE3 transcriptionally regulated by activating transcription factor 3 promotes HCC ferroptosis via ERK and JNK signaling pathway","volume":"165","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"2026071304000824000_2026.07.08.737095v1.87","doi-asserted-by":"crossref","unstructured":"Chiu, C.L. , Li, C.G. , Verschueren, E. , Wen, R.M. , Zhang, D. , Gordon, C.A. , Zhao, H. , Giaccia, A.J. and Brooks, J.D . (2023) NUSAP1 Binds ILF2 to Modulate R-Loop Accumulation and DNA Damage in Prostate Cancer. Int J Mol Sci, 24.","DOI":"10.3390\/ijms24076258"},{"key":"2026071304000824000_2026.07.08.737095v1.88","doi-asserted-by":"crossref","first-page":"15971","DOI":"10.18632\/oncotarget.13278","article-title":"TLE1 function and therapeutic potential in cancer","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"2026071304000824000_2026.07.08.737095v1.89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2023.12.009","article-title":"Discovery of a PROTAC degrader for METTL3-METTL14 complex","volume":"31","year":"2024","journal-title":"Cell Chem Biol"},{"key":"2026071304000824000_2026.07.08.737095v1.90","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00044-025-03464-8","article-title":"Discovery of CRBN-recruiting PROTAC degraders of the METTL3-METTL14 complex","volume":"34","year":"2025","journal-title":"Med Chem Res"},{"key":"2026071304000824000_2026.07.08.737095v1.91","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1039\/D5MD00359H","article-title":"Structure-guided design of a methyltransferase-like 3 (METTL3) proteolysis targeting chimera (PROTAC) incorporating an indole-nicotinamide chemotype","volume":"16","year":"2025","journal-title":"RSC Med Chem"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.07.08.737095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:00:17Z","timestamp":1783940417000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.07.08.737095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":91,"URL":"https:\/\/doi.org\/10.64898\/2026.07.08.737095","relation":{},"subject":[],"published":{"date-parts":[[2026,7,9]]},"subtype":"preprint"}}